Generics (UK) Ltd v Synaptech Inc [2009] EWHC 659 (Ch) (20 May 2009)
The ECJ's judgment in Hässle AB v Ratiopharm GmbH is binding and establishes that only Directive 65/65 compliant marketing authorisations are relevant for calculating the term of an SPC under Article 13(1) of Regulation 1768/92. Earlier authorisations not compliant with Directive 65/65 cannot be used for this purpose.
- Citation
- [2009] EWHC 659 (Ch)
- Parties
- Claimant: Generics (UK) Limited; Defendant: Synaptech Inc
- Jurisdiction
- England and Wales
- Judgment Date
- 20 May 2009
- Procedural Posture
- Patent Rectification Action / Judgment After Streamlined Procedure, No Disclosure or Cross Examination
- Outcome
- Claim dismissed
- Legal Topics
- Supplementary Protection Certificates, Patent Term Extension, Marketing Authorisation, Directive 65/65/eec Compliance
Case Brief
Summary, issues, holding and outcome
More case intelligence is available
Unlock the full research layer for this judgment.
Parties
Generics (UK) Limited
Claimant
Synaptech Inc
Defendant
Procedural Posture
Patent Rectification Action / Judgment After Streamlined Procedure, No Disclosure or Cross Examination
Legal Issues
- 1 Whether the first marketing authorisation under Article 13(1) of the SPC Regulation must be Directive 65/65 compliant or whether any prior authorisation suffices for SPC term calculation
Ratio Decidendi
The ECJ's judgment in Hässle AB v Ratiopharm GmbH is binding and establishes that only Directive 65/65 compliant marketing authorisations are relevant for calculating the term of an SPC under Article 13(1) of Regulation 1768/92. Earlier authorisations not compliant with Directive 65/65 cannot be used for this purpose.
Court Disposition
Claim dismissed
Orders
- Claimant's action for rectification of the patent register is dismissed
- No rectification of SPC term; SPC expiry remains 15 January 2012
Full Case Text
Judgment text and source record
Sign in to read
Sign in to read the full judgment text
Sign in to read the full judgment text. Downloads and additional research tools may depend on your plan.
Sign in to read the full judgment